Nēsos is a clinical stage company developing disease modifying digital therapeutics targeting the autonomic nervous system’s control of the immune response. Nēsos clinical efforts are in inflammatory mediated diseases with a current focus on autoimmune, neurological and neuropsychiatric disorders.

Konstantinos Alataris PhD, the founder and former CEO of Nevro (NYSE: NVRO), and a team of neuroscientists and engineers that have developed neurostimulation based therapeutics for neurological disorders are the founding team of Nēsos. Nevro under Konstantinos' leadership advanced Senza®, its implantable neuromodulator therapeutic, from concept to commercialization for chronic pain, subsequently expanding its approved indications.

Nēsos is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University Of California, San Francisco (UCSF).